Tumor necrosis factor gene polymorphism and septic shock in surgical infection

ObjectivesTo evaluate the relationship of the genotype distribution of the tumor necrosis factor (TNF)-&agr; polymorphism with regard to the plasma TNF-&agr; concentration and the development of septic shock as well as mortality of infected patients in a surgical intensive care unit (SICU). DesignA total of 112 postoperative critically ill infected patients were prospectively enrolled. SettingSICU of a tertiary university-affiliated medical center. PatientsPatients who were consecutively admitted to the SICU because of surgical infection with sepsis. InterventionBlood sampling. Measurements and Main ResultsBlood sample was obtained 24 hrs after intensive care unit (ICU) admission or within 2 hrs after the onset of septic shock to determine the plasma TNF-&agr; level and to analyze the genotype of the biallelic polymorphism of the TNF-&agr;. ResultsThe allele frequency of the TNF2 in our infected ICU patients was 12%. Forty-two (37.5%) patients admitted fulfilled the criteria of septic shock during their ICU stay. Patients carrying the TNF2 allele were not more likely to develop septic shock, nor did they have a higher mortality rate. In the patients with septic shock, those carrying the TNF2 allele had a significantly higher mortality rate than those with the homozygous TNF1 genotype (92% vs. 62%, p < .05). In those who developed septic shock, the TNF2 allele was significantly associated with higher TNF levels. ConclusionIn patients admitted to SICU with surgical infection, the frequency of TNF2 allele was higher than in the general population. SICU patients with TNF2 allele did not show a higher incidence of developing septic shock, nor was there a higher baseline TNF-&agr; level after infection. However, once septic shock had developed, the mortality rate was higher in those patients carrying the TNF2 allele.

[1]  Song-Lih Huang,et al.  Tumor Necrosis Factor- α Gene Polymorphism in Chronic Bronchitis , 1997 .

[2]  R. Shenkar,et al.  Hemorrhage Activates Myocardial NF?B and Increases TNF-a in the Heart , 1997 .

[3]  J. Cobb,et al.  Nitric oxide and septic shock. , 1996, JAMA.

[4]  T. Yen,et al.  Perioperative plasma concentrations of tumor necrosis factor-alpha and interleukin-6 in infected patients. , 1996, Critical care medicine.

[5]  F. Stüber,et al.  A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. , 1996, Critical care medicine.

[6]  O. Griffith,et al.  NG-methyl-L-arginine, an inhibitor of nitric oxide synthase, reverses interleukin-2-induced hypotension. , 1995, Critical care medicine.

[7]  D. Kwiatkowski,et al.  Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria , 1994, Nature.

[8]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[9]  J. H. Wilson,et al.  Osteoporosis and fracture complications in an amenorrhoeic athlete. , 1994, British journal of rheumatology.

[10]  R. Bone,et al.  Role of tumor necrosis factor-α in disease states and inflammation , 1993 .

[11]  J. Lorente,et al.  L‐arginine pathway in the sepsis syndrome , 1993, Critical care medicine.

[12]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[13]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[14]  I. Chaudry,et al.  Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? , 1992, Archives of surgery.

[15]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute‐phase proteins during the treatment of severe sepsis in humans , 1992, Critical care medicine.

[16]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .

[17]  H. Mcdevitt,et al.  Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Lamy,et al.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. , 1989, Critical care medicine.

[19]  W. Buurman,et al.  Plasma tumor necrosis factor and mortality in critically ill septic patients. , 1989, Critical care medicine.

[20]  J. Nerup,et al.  Endotoxin‐Stimulated Human Monocyte Secretion of Interleukin 1, Tumour Necrosis Factor Alpha, and Prostaglandin E2 Shows Stable Interindividual Differences , 1988, Scandinavian journal of immunology.

[21]  B. Beutler,et al.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. , 1986, Science.

[22]  R. Shenkar,et al.  Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. , 1997, Journal of molecular and cellular cardiology.

[23]  C. Su,et al.  Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. , 1997, American journal of respiratory and critical care medicine.

[24]  I. Udalova,et al.  -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. , 1995, Journal of inflammation.

[25]  D. Kwiatkowski,et al.  Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. , 1994, Nature.

[26]  R. Bone,et al.  Role of tumor necrosis factor-alpha in disease states and inflammation. , 1993, Critical care medicine.